Table 3.

Association analysis between anti-CENP-Q antibody in systemic sclerosis sera samples and clinical manifestations and laboratory features. Bold type indicates p values < 0.05, which are statistically significant. Data are percentages unless otherwise indicated.

		ACA (+)			All
Anti-CENP-Q	+	−	p*	+	−	p*
No. Cases	11	24		11	175
Disease pattern, limited/diffuse	10/1	19/5	0.6400	10/1	93/82	0.0243
Sex, men/women	1/10	1/23	0.5361	1/10	14/161	1.0000
Age, mean ± SD, yrs	49.2 ± 12.7	46.9 ± 9.8	0.5674	49.2 ± 12.7	44.3 ± 12.3	0.2040
Anti-CENP-B	100	95.8	1.0000	100	13.1	< 0.0001
Anti-CENP-A	100	87.5	0.5361	100	12.0	< 0.0001
Anti-Scl-70	9.1	12.5	1.0000	9.1	46.3	0.0244
Raynaud phenomenon	90.9	100	0.3143	90.9	95.4	0.4295
Arthralgia/arthritis	36.4	33.3	1.0000	36.4	53.7	0.4198
Digital ulcers	18.2	20.8	1.0000	18.2	28.0	0.7300
Muscle weakness	36.4	12.5	0.1715	36.4	29.7	0.7365
GI manifestations	18.2	4.2	0.2269	18.2	20.0	1.0000
Cardiac involvement	9.1	8.3	1.0000	9.1	8.6	1.0000
Renal crisis	9.1	0	0.3143	9.1	1.7	0.2180
Kidney involvement	9.1	0	0.3143	9.1	3.4	0.3521
Lung involvement	0	4.2	1.0000	0.0	20.0	0.1290
Interstitial lung disease	27.3	33.3	1.0000	27.3	73.1	0.0030
PAH	0	8.3	1.0000	0.0	17.1	0.2165
IgG, mean ± SD g/l	15.8 ± 6.2	14.3 ± 4	0.4191	15.8 ± 6.2	16.5 ± 6.3	0.7288
IgA, mean ± SD g/l	2.8 ± 0.9	2.4 ± 1.3	0.4034	2.8 ± 0.9	2.7 ± 1.3	0.8354
IgM, mean ± SD g/l	1.7 ± 0.6	1.7 ± 1.2	0.9001	1.7 ± 0.6	1.4 ± 0.8	0.3017
ESR, mean ± SD mm/h	17.6 ± 15.6	16.4 ± 17.4	0.8451	17.6 ± 15.6	23.4 ± 24.7	0.4442

^*P values calculated using Pearson’s chi-square or Fisher’s exact test and 2-tailed T-test if necessary.

CENP: centromere protein; ACA: anticentromere antibodies; GI: gastrointestinal; PAH: pulmonary arterial hypertension; ESR: erythrocyte sedimentation rate.